Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + oxaliplatin + 5-fluorouracil
- Development stage
- Phase 2
- Lead developer
- Fudan University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
EOF5 is a combination chemotherapy regimen consisting of epirubicin, oxaliplatin, and a 5-day continuous infusion of 5-fluorouracil. It is primarily investigated for the treatment of advanced or metastatic gastric cancer. The regimen combines three distinct antineoplastic agents to inhibit tumor growth through multiple pathways: epirubicin, an anthracycline that intercalates DNA and inhibits topoisomerase II; oxaliplatin, a platinum-based agent that forms DNA cross-links; and 5-fluorouracil, a pyrimidine analog that inhibits thymidylate synthase. The specific 5-day continuous infusion schedule of 5-fluorouracil is intended to maximize exposure during the S-phase of the cell cycle, potentially improving efficacy and tolerability compared to bolus administration. This regimen has been evaluated in Phase II clinical trials, particularly by Fudan University, for patients with unresectable advanced or metastatic gastric cancer.
- Other names
- EOF5 regimenEOF-5 regimenEOF 5 regimen
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on epirubicin + oxaliplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + oxaliplatin + 5-fluorouracil.